J Clin Invest (2019) 129(10):4492505
Exit Edition 3 Major Industries And Their Next-Gen Disruptors CHAINALYSIS FOUNDERS: Michael Gronager (CEO), Jonathan Levin, Jan Moller EQUITY RAISED: $53 million ESTIMATED 2018 REVENUE: $8 million LEAD INVESTORS: Accel, Benchmark New York-based Chainalysis makes cryptocurrency investigation software that can shine light on how people use bitcoin, ethereum, litecoin and more
While Novo Nordisk and rival obesity therapy manufacturer Eli Lilly are starting to overcome the production constraints that coupled with massive demand have resulted in shortages, Noom's WSJ ad calls for US policymakers to keep the status in place "until GLP-1s cost the same in NYC and London." The FDA has received adverse event reports involving patients who have used them and has taken action against some compounders making versions available based on salt forms of the drug that are unapproved, including semaglutide sodium and semaglutide acetate, so the availability of compounded forms has become controversial
PlexusDx published pricing PlexusDx posts its numbers openly on the Weight Management Protocols : Semaglutide Injection at $189 per month, Tirzepatide Injection at $289 per month, and a microdose option at $129 per month, with the Precision Peptide Genetic Test at $298